Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $26.9300 (-15.15%) ($26.9300 - $26.9300) on Mon. Nov. 15, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.81% (three month average) | RSI | 36 | Latest Price | $26.9300(-15.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -4.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(66%) IBB(63%) ARKK(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.905% in a week (0% probabilities). VIXM(-49%) VXX(-40%) UUP(-20%) UNG(-6%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.905% (StdDev 3.81%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
Resistance Level | $32.41 | 5 Day Moving Average | $31.96(-15.74%) | 10 Day Moving Average | $32.96(-18.29%) | 20 Day Moving Average | $32.41(-16.91%) | To recent high | -24.3% | To recent low | 24.2% | Market Cap | $3.411b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |